The Food and Drug Administration (FDA) has cleared the Kimberly-Clark pediatric/child face mask, designed to be worn in hospitals and healthcare facilities to help reduce the spread of airborne respiratory tract bacteria, viruses, and other pathogens.
The mask is designed to fit children ages 5 years to 12 years. Children do not breathe as forcefully as adults, particularly children with respiratory infections, so the face mask is less resistant to airflow than an adult mask.
"Children are not small adults," says Susan Cummins, MD, chief pediatric medical officer at FDAs Center for Devices and Radiological Health. "This pediatric face mask helps fill an unmet need for medical devices that are specifically designed for childrens unique anatomy and growing bodies."
Performance tests reviewed by the FDA showed that air flow and filtering ability of the mask were appropriate for children. The mask, cleared on Sept. 23, 2011, includes specific fitting instructions for the adult who assists the child in using the device. Adult supervision of any child wearing a face mask is an important safety recommendation.
The mask should not be used on patients showing signs of shortness of breath, chest pain, chest pressure, indrawing of the lower chest wall, dizziness, or confusion.
Unraveling a Candida auris Outbreak: Infection Control Challenges in a Burn ICU
March 19th 2025A Candida auris outbreak in a burn intensive care unit (BICU) in Illinois has highlighted the persistent challenges of infection control in high-risk health care settings. Despite rigorous containment efforts, this multidrug-resistant fungal pathogen continued to spread, underscoring the need for enhanced prevention strategies, environmental monitoring, and genomic surveillance.
Unmasking Long COVID: Dr Noah Greenspan on Recovery, Research Gaps, and the Future of Treatment
March 18th 2025Dr Noah Greenspan discusses the evolving understanding of long COVID, current treatment strategies, diagnostic challenges, and the critical need for research and awareness in post-viral syndromes.